Novo Nordisk Free Cash Flow 2010-2024 | NVO
Novo Nordisk annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Novo Nordisk free cash flow for the quarter ending September 30, 2024 was 11,438.98, a year-over-year.
- Novo Nordisk free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.
- Novo Nordisk annual free cash flow for 2023 was $12.066B, a 27.68% increase from 2022.
- Novo Nordisk annual free cash flow for 2022 was $9.451B, a 22.06% increase from 2021.
- Novo Nordisk annual free cash flow for 2021 was $7.743B, a 9.55% increase from 2020.
| Novo Nordisk Annual Free Cash Flow |
| 2023 |
12,066.41 |
| 2022 |
9,450.53 |
| 2021 |
7,742.60 |
| 2020 |
7,067.58 |
| 2019 |
5,674.31 |
| 2018 |
5,350.43 |
| 2017 |
5,096.40 |
| 2016 |
6,130.20 |
| 2015 |
4,922.01 |
| 2014 |
4,939.98 |
| 2013 |
4,049.10 |
| 2012 |
3,265.06 |
| 2011 |
3,433.54 |
| 2010 |
2,918.95 |
| 2009 |
2,387.51 |
| Novo Nordisk Quarterly Free Cash Flow |
| 2024-09-30 |
11,438.98 |
| 2024-06-30 |
6,619.47 |
| 2024-03-31 |
850.30 |
| 2023-12-31 |
12,066.41 |
| 2023-09-30 |
12,111.87 |
| 2023-06-30 |
6,986.50 |
| 2023-03-31 |
3,619.94 |
| 2022-12-31 |
9,450.53 |
| 2022-09-30 |
8,740.52 |
| 2022-06-30 |
6,233.66 |
| 2022-03-31 |
3,327.55 |
| 2021-12-31 |
7,742.60 |
| 2021-09-30 |
8,521.74 |
| 2021-06-30 |
5,413.98 |
| 2021-03-31 |
1,597.17 |
| 2020-12-31 |
7,067.58 |
| 2020-09-30 |
7,453.58 |
| 2020-06-30 |
4,632.91 |
| 2020-03-31 |
1,232.56 |
| 2019-12-31 |
5,674.31 |
| 2019-09-30 |
5,154.51 |
| 2019-06-30 |
3,032.78 |
| 2019-03-31 |
1,102.84 |
| 2018-12-31 |
5,350.43 |
| 2018-09-30 |
4,732.73 |
| 2018-06-30 |
3,382.59 |
| 2018-03-31 |
1,279.20 |
| 2017-12-31 |
5,096.40 |
| 2017-09-30 |
4,746.32 |
| 2017-06-30 |
2,819.27 |
| 2017-03-31 |
1,504.84 |
| 2016-12-31 |
6,130.20 |
| 2016-09-30 |
4,890.30 |
| 2016-06-30 |
2,916.02 |
| 2016-03-31 |
944.19 |
| 2015-12-31 |
4,922.01 |
| 2015-09-30 |
3,748.37 |
| 2015-06-30 |
2,118.96 |
| 2015-03-31 |
506.65 |
| 2014-12-31 |
4,939.98 |
| 2014-09-30 |
3,899.98 |
| 2014-06-30 |
1,966.48 |
| 2014-03-31 |
620.17 |
| 2013-12-31 |
4,049.10 |
| 2013-09-30 |
3,214.92 |
| 2013-06-30 |
2,241.33 |
| 2013-03-31 |
1,113.61 |
| 2012-12-31 |
3,265.06 |
| 2012-09-30 |
3,090.85 |
| 2012-06-30 |
1,964.22 |
| 2012-03-31 |
1,128.14 |
| 2011-12-31 |
3,433.54 |
| 2011-09-30 |
2,958.68 |
| 2011-06-30 |
1,633.36 |
| 2011-03-31 |
836.12 |
| 2010-12-31 |
2,918.95 |
| 2010-09-30 |
2,181.01 |
| 2010-06-30 |
1,204.52 |
| 2010-03-31 |
662.72 |
| 2009-12-31 |
2,387.51 |
| 2009-09-30 |
1,939.01 |
| 2009-06-30 |
1,058.26 |
| 2009-03-31 |
653.63 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$381.440B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
